Formulation and Systemic Therapy

Clicks: 14
ID: 328421
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #220 of 243 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 243 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
An 81-year-old woman receiving upadacitinib, a JAK-1 inhibitor, for rheumatoid arthritis developed herpes zoster ophthalmicus with significant ophthalmic morbidity and varicella-zoster virus encephalitis. Medication reconciliation revealed continued JAK-1 inhibition during early presentations. This case highlights the importance of structured vaccination review and documentation before initiating targeted immunomodulatory therapy and underscores the potential severity of neuro-ophthalmic VZV in patients receiving JAK inhibition.
Reference Key
openalex_W7212353166 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Taherah Khan, Foteini Moniati, D. Thompson
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag395
URL
https://doi.org/10.1093/ced/llag395
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.